Abstracts
3427226
(#56) Use of an Aripiprazole Lauroxil Injection Administered Once Every Month, 6 Weeks, or 2 Months in People With Schizophrenia: A Clinician-Focused Summary of Study Data
Abstract: Introduction: Aripiprazole lauroxil (AL) is a long-acting injectable form of the antipsychotic aripiprazole designed to provide consistent plasma levels for up to 4, 6, or 8 weeks between injections. This presentation provides a clinician-focused summary of key findings reported in recently published articles about AL, including treatment initiation, dosing options, effects on symptoms of schizophrenia, and side effects in study participants.
Methods: Articles reviewed included clinical studies on AL safety and efficacy in patients with schizophrenia and analyses supporting initiation and dosing options.
Results: In clinical studies, patients who started taking AL during an episode of worsening symptoms of schizophrenia had meaningful improvement in their symptoms at the 4- and 12-week study assessments, and, on average, treatment effect was maintained for up to 3.5 years. The side effects were similar to those reported in other studies for oral aripiprazole, with the addition of injection site pain as a commonly reported adverse event. Patients can initiate treatment with AL using a 1-day initiation regimen with their first dose, allowing initiation of AL treatment during an office visit or brief hospital stay without having to take daily oral aripiprazole supplementation afterward. Healthcare providers can choose from several dose strengths and intervals to best fit the treatment needs of individual patients.
Conclusions: The safety and efficacy profile of AL, combined with its dosing and initiation options, makes it an important treatment option in both inpatient and outpatient settings for people with schizophrenia.
Short Description: This presentation provides a clinician-focused summary of key published findings for the long-acting injectable aripiprazole lauroxil (AL). In clinical studies, patients who initiated AL during acute hospitalization for schizophrenia had meaningful improvement in their symptoms after 4- or 12-week treatment, with durable effects for up to 3.5 years. AL can be started using a 1-day initiation regimen with the first dose, and healthcare providers can choose from several dose strengths and intervals for individual patients.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
Methods: Articles reviewed included clinical studies on AL safety and efficacy in patients with schizophrenia and analyses supporting initiation and dosing options.
Results: In clinical studies, patients who started taking AL during an episode of worsening symptoms of schizophrenia had meaningful improvement in their symptoms at the 4- and 12-week study assessments, and, on average, treatment effect was maintained for up to 3.5 years. The side effects were similar to those reported in other studies for oral aripiprazole, with the addition of injection site pain as a commonly reported adverse event. Patients can initiate treatment with AL using a 1-day initiation regimen with their first dose, allowing initiation of AL treatment during an office visit or brief hospital stay without having to take daily oral aripiprazole supplementation afterward. Healthcare providers can choose from several dose strengths and intervals to best fit the treatment needs of individual patients.
Conclusions: The safety and efficacy profile of AL, combined with its dosing and initiation options, makes it an important treatment option in both inpatient and outpatient settings for people with schizophrenia.
Short Description: This presentation provides a clinician-focused summary of key published findings for the long-acting injectable aripiprazole lauroxil (AL). In clinical studies, patients who initiated AL during acute hospitalization for schizophrenia had meaningful improvement in their symptoms after 4- or 12-week treatment, with durable effects for up to 3.5 years. AL can be started using a 1-day initiation regimen with the first dose, and healthcare providers can choose from several dose strengths and intervals for individual patients.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
